Bluebird Bio’s (BLUE) Buy Rating Reaffirmed at Janney Montgomery Scott
Bluebird Bio Inc. (NASDAQ:BLUE)‘s stock had its “buy” rating reissued by investment analysts at Janney Montgomery Scott in a research note issued to investors on Thursday.
Other analysts have also recently issued reports about the company. Maxim Group reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Bluebird Bio in a research report on Monday, September 12th. BTIG Research reaffirmed a “buy” rating and issued a $72.00 price objective on shares of Bluebird Bio in a research report on Sunday, September 11th. Goldman Sachs Group Inc. reaffirmed a “buy” rating and issued a $135.00 price objective on shares of Bluebird Bio in a research report on Thursday, September 8th. Leerink Swann reaffirmed a “buy” rating on shares of Bluebird Bio in a research report on Friday, September 9th. Finally, Piper Jaffray Cos. set a $95.00 target price on Bluebird Bio and gave the stock a “buy” rating in a research note on Thursday, September 8th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $82.82.
Bluebird Bio (NASDAQ:BLUE) traded up 2.32% during trading on Thursday, reaching $63.95. The company’s stock had a trading volume of 505,529 shares. Bluebird Bio has a 1-year low of $35.37 and a 1-year high of $94.61. The company’s 50 day moving average price is $56.23 and its 200-day moving average price is $52.68. The stock’s market cap is $2.39 billion.
Bluebird Bio (NASDAQ:BLUE) last released its quarterly earnings data on Wednesday, November 2nd. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.59) by $0.48. Bluebird Bio had a negative net margin of 3,941.72% and a negative return on equity of 30.79%. The business earned $1.55 million during the quarter, compared to analyst estimates of $1.82 million. During the same period in the previous year, the business earned ($1.18) earnings per share. The business’s quarterly revenue was up 17.4% on a year-over-year basis. Equities analysts forecast that Bluebird Bio will post ($7.05) earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Bluebird Bio’s (BLUE) Buy Rating Reaffirmed at Janney Montgomery Scott” was published by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark legislation. The legal version of this story can be accessed at https://www.thecerbatgem.com/2016/11/25/bluebird-bios-blue-buy-rating-reaffirmed-at-janney-montgomery-scott.html.
In other Bluebird Bio news, insider Eric Sullivan sold 416 shares of the firm’s stock in a transaction on Monday, October 3rd. The stock was sold at an average price of $67.00, for a total transaction of $27,872.00. Following the transaction, the insider now owns 5,891 shares in the company, valued at approximately $394,697. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 3.50% of the company’s stock.
A number of institutional investors have recently bought and sold shares of BLUE. California State Teachers Retirement System raised its position in Bluebird Bio by 2.2% in the second quarter. California State Teachers Retirement System now owns 77,687 shares of the company’s stock worth $3,363,000 after buying an additional 1,682 shares during the period. Vanguard Group Inc. raised its position in shares of Bluebird Bio by 14.2% in the second quarter. Vanguard Group Inc. now owns 2,680,871 shares of the company’s stock valued at $116,055,000 after buying an additional 333,396 shares during the last quarter. Swiss National Bank raised its position in shares of Bluebird Bio by 10.6% in the second quarter. Swiss National Bank now owns 59,707 shares of the company’s stock valued at $2,585,000 after buying an additional 5,700 shares during the last quarter. RS Investment Management Co. LLC raised its position in shares of Bluebird Bio by 9.0% in the second quarter. RS Investment Management Co. LLC now owns 575,093 shares of the company’s stock valued at $24,896,000 after buying an additional 47,339 shares during the last quarter. Finally, Geduld E E acquired a new position in shares of Bluebird Bio during the second quarter valued at about $424,000.
Bluebird Bio Company Profile
bluebird bio, Inc is a biotechnology company. The Company is focused on developing transformative gene therapies for severe genetic and rare diseases and in the field of T cell-based immunotherapy. Its gene therapy clinical programs include LentiGlobin product candidate to treat transfusion-dependent B-thalassemia (TDT) and severe sickle cell disease (SCD), and Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD), a rare hereditary neurological disorder.
Receive News & Stock Ratings for Bluebird Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluebird Bio Inc. and related stocks with our FREE daily email newsletter.